Introduction: Gene-modified cell vaccines are now considered to be the best way to achieve immunotherapy for a variety of cancers including prostate cancer (PCa). XAGE-1b is a member of the cancer/testis antigen family which has demonstrated strong immunogenicity. We investigated whether XAGE-1b is an ideal target for PCa immunotherapy. Materials and Methods: The recombinant eukaryotic expression vector pDisplay-XAGE-1b was constructed. Then the recombinant vector was transfected into Myc-CaP cells and its immunogenicity in vitro was studied. After transfection, the Myc-CaP-XAGE-1b cells were injected into FVB mice subcutaneously. Tumor growth was periodically observed and the anti-tumor effect and mechanism in vivo were further studied. Results: The recombinant vector was correctly constructed by DNA sequencing and restriction endonuclease digestion. Myc-CaP cells were successfully transfected with XAGE-1b gene by immunofluorescence staining and Western blot. The transfected cells exhibited increased IFN-γ secretion, decreased IL-6 secretion and enhanced killing activity. Tumor grew slower in XAGE-1b-modified FVB mice than in wild-type FVB mice. High dendritic cell expression and low myeloid-derived suppressor cell expression were observed in tumor tissues expressed with XAGE-1b. Conclusions: XAGE-1b gene transfection could significantly enhance the immunogenicity of Myc-CaP cells. Therefore, XAGE-1b may be an attractive target for antigen-specific immunotherapy in PCa.

Keywords:
Prostate cancer, Immunotherapy, Eukaryotic expression vector, Cancer/testis antigen, XAGE-1b
1.
Caballero OL, Chen YT: Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009;100:2014-2021.
2.
Sang M, Lian Y, Zhou X, Shan B: MAGE-A family: attractive targets for cancer immunotherapy. Vaccine 2011;29:8496-8500.
3.
Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-625.
4.
Meek DW, Marcar L: MAGE-A antigens as targets in tumour therapy. Cancer Lett 2012;324:126-132.
5.
Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, Knuth A, Chen YT, Old LJ: NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006;95:1-30.
6.
Brinkmann U, Vasmatzis G, Lee B, Pastan I: Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res 1999;59:1445-1448.
7.
Liu XF, Helman LJ, Yeung C, Bera TK, Lee B, Pastan I: XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma. Cancer Res 2000;60:4752-4755.
8.
Koizumi F, Noguchi Y, Saika T, Nakagawa K, Sato S, Eldib AM, Nasu Y, Kumon H, Nakayama E: XAGE-1 mRNA expression in prostate cancer and antibody response in patients. Microbiol Immunol 2005;49:471-476.
9.
Nakagawa K, Noguchi Y, Uenaka A, Sato S, Okumura H, Tanaka M, Shimono M, Ali Eldib AM, Ono T, Ohara N, Yoshino T, Yamashita K, Tsunoda T, Aoe M, Shimizu N, Nakayama E: XAGE-1 expression in non-small cell lung cancer and antibody response in patients. Clin Cancer Res 2005;11:5496-5503.
10.
Sato S, Noguchi Y, Ohara N, Uenaka A, Shimono M, Nakagawa K, Koizumi F, Ishida T, Yoshino T, Shiratori Y, Nakayama E: Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors. Cancer Immun 2007;7:5.
11.
Stames CO: Coley's toxins in perspective. Nature 1992;357:11-12.
12.
Scanlan MJ, Simpson AJ, Old LJ: The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1.
13.
Shamseddine A, Farhat FS, Elias E, Khauli RB, Saleh A, Bulbul MA: High-dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: a phase II study. Urol Int 2013;90:56-61.
14.
Kulkarni P, Shiraishi T, Rajagopalan K, Kim R, Mooney SM, Getzenberg RH: Cancer/testis antigens and urological malignancies. Nat Rev Urol 2012;9:386-396.
15.
Huang CJ, Chen RH, Vannelli T, Lee F, Ritter E, Ritter G, Old LJ, Batt CA: Expression and purification of the cancer antigen SSX2: a potential cancer vaccine. Protein Expr Purif 2007;56:212-219.
16.
Ebert LM, MacRaild SE, Zanker D, Davis ID, Cebon J, Chen W: A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS One 2012;7:e48424.
17.
Ko YH, Miyake H, Behnsawy HM, Cheon J, Fujisawa M: Limited significance of activated Akt-mammalian target of rapamycin signaling pathway in prostate cancer progression. Urol Int 2014;93:146-151.
18.
Shantha Kumara HM, Grieco MJ, Caballero OL, Su T, Ahmed A, Ritter E, Gnjatic S, Cekic V, Old LJ, Simpson AJ, Cordon-Cardo C, Whelan RL: MAGE-A3 is highly expressed in a subset of colorectal cancer patients. Cancer Immun 2012;12:16.
19.
Palucka K, Banchereau J: Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013;39:38-48.
20.
Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers CL: Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res 2005;65:11565-11571.
21.
van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS: Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-225.
22.
Tilley WD, Wilson CM, Marcelli M, McPhaul MJ: Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990;50:5382-5386.
23.
Placek K, Coffre M, Maiella S, Bianchi E, Rogge L: Genetic and epigenetic networks controlling T helper 1 cell differentiation. Immunology 2009;127:155-162.
24.
Bromberg J, Wang TC: Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009;15:79-80.
25.
Piriou L, Chilmonczyk S, Genetet N, Albina E: Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species. Cytometry 2000;41:289-297.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.